Date Title Description PDF
10 May 2023 On P&L The Company releases the press release related to the first quarter 2023 financial results Download
25 Apr 2023 On business and financial situation ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) Download
21 Feb 2023 On business and financial situation The Company releases the full year 2022 financial results presentation. Download
21 Feb 2023 On business and financial situation The Company releases the press release related to the full year 2022 financial results. Download
21 Feb 2023 On business and financial situation The company releases the Integrated Report for the year 2022 Download

Pages

Date Title Description PDF
03 Nov 2021 On business and financial situation The Company releases the press release related to the first nine months 2021 financial results Download
21 Oct 2021 On business and financial situation The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). Download
21 Oct 2021 Liquidity and counterparty agreements Download
07 Oct 2021 Liquidity and counterparty agreements Download
04 Oct 2021 Liquidity and counterparty agreements Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages